Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12493034-B2

Patent

Publication Date

2025-12-09

Expiration Date


Abstract

An embodiment relates to a reagent buffer comprising a zwitterionic sulfonic solution, a non-ionic surfactant solution, and a buffer solution, wherein the reagent buffer has a pH range of about 7.0 to about 8.0 and a circular dichroism with an absorbance peak more than 0 at 190 nm and 225 nm. In an embodiment, the reagent buffer is configured to be a reagent buffer for a lateral flow immunoassay for detection of COVID-19.

Core Innovation

The invention relates to a reagent buffer for a lateral flow immunoassay used for rapid SARS-CoV-2 antigen testing. The reagent buffer includes a zwitterionic sulfonic solution combined with a non-ionic surfactant solution mixture and an additional buffer solution, where the pH is about 7.0 to 8.0. The reagent buffer further includes a quality-control feature associated with circular dichroism quality-control absorbance peaks greater than 0 at about 190 nm and about 225 nm.

The described approach addresses reagent-buffer roles in an antigen test workflow, including antigen extraction without denaturing binding sites, strip rehydration, mobilization of conjugate beads, and reduction of nonspecific background. The buffer composition is configured to improve test signal quality by managing nonspecific background signal while supporting antigen binding performance.

The disclosure provides working-example results in which the zwitterionic sulfonic solution and non-ionic surfactant components are optimized to improve flow and clarity and reduce background for the SARS-CoV-2 antigen lateral flow immunoassay. The described quality-control approach uses circular dichroism spectroscopy equivalence, and the reported performance includes equivalent limit of detection versus predicate buffers.

Claims Coverage

Not explicitly described in patent.

Not explicitly described in patent.

Stated Advantages

Improves flow and clarity in the lateral flow immunoassay antigen test.

Reduces non-specific background signal in the SARS-CoV-2 antigen lateral flow immunoassay.

Supports antigen extraction without denaturing binding sites.

Achieves equivalent limit of detection versus predicate SARS-CoV-2 antigen lateral flow immunoassay buffers.

Provides quality assurance/quality control using circular dichroism absorbance peaks at about 190 nm and about 225 nm.

Documented Applications

Compatibility with other SARS-CoV-2 antigen lateral flow immunoassay formats.

Downstream use for protein antigen testing and RNA preservation for PCR.

Wastewater antigen extraction [procedural detail omitted for safety].

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.